Showing results (51-60 of 676) with videos related to
Sort By:
Pageof 68
Neurology|May 13, 2016
Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort studyMathias Buttmann, Linda Seuffert, Uwe Mäder, et al.Journal of Neuroimmunology|September 22, 2007
TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic responseMathias Buttmann, Cornelia Merzyn, Harald H Hofstetter, et al.Stroke|July 9, 2011
Restoring neuronal function after stroke by cell replacement: anatomic and functional considerationsMarcel Dihné, Hans-Peter Hartung, Rüdiger J SeitzPharmacology & Therapeutics|August 13, 2005
Therapeutic role of mitoxantrone in multiple sclerosisOliver Neuhaus, Bernd C Kieseier, Hans-Peter HartungCurrent Opinion in Neurology|May 14, 2005
Multiple sclerosis--novel insights and new therapeutic strategiesBernd C Kieseier, Bernhard Hemmer, Hans-Peter HartungJournal of Neurology|November 19, 2004
What do we know about the mechanism of action of disease-modifying treatments in MS?Hans-Peter Hartung, Amit Bar-Or, Yannis ZoukosNeurology|May 30, 2018
150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacyHelmar C Lehmann, Alastair Compston, Hans-Peter HartungTrends in Pharmacological Sciences|May 25, 2015
IVIg for relapsing-remitting multiple sclerosis: promises and uncertaintiesJagadeesh Bayry, Hans-Peter Hartung, Srini V KaveriCurrent Opinion in Neurology|September 14, 2006
Immune circuitry in the peripheral nervous systemBernd C Kieseier, Hans-Peter Hartung, Heinz WiendlJournal of Neurology|July 21, 2004
Biologic role of interferon beta in multiple sclerosisAlfons Billiau, Bernd C Kieseier, Hans-Peter HartungPageof 68